Dimensional Fund Advisors’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $46.6M | Buy |
2,060,597
+110,584
| +6% | +$2.46M | 0.01% | 1542 |
|
|
2025
Q4 | $50.5M | Sell |
1,950,013
-213,460
| -10% | -$5.08M | 0.01% | 1505 |
|
|
2025
Q3 | $55.8M | Buy |
2,163,473
+11,831
| +0.5% | +$291K | 0.01% | 1461 |
|
|
2025
Q2 | $51.4M | Buy |
2,151,642
+102,211
| +5% | +$2.58M | 0.01% | 1481 |
|
|
2025
Q1 | $50.9M | Buy |
2,049,431
+217,215
| +12% | +$5.2M | 0.01% | 1468 |
|
|
2024
Q4 | $34.5M | Sell |
1,832,216
-40,154
| -2% | -$705K | 0.01% | 1728 |
|
|
2024
Q3 | $28.2M | Buy |
1,872,370
+44,305
| +2% | +$757K | 0.01% | 1831 |
|
|
2024
Q2 | $52.3M | Buy |
1,828,065
+198,936
| +12% | +$5.66M | 0.01% | 1432 |
|
|
2024
Q1 | $47.6M | Buy |
1,629,129
+217,362
| +15% | +$6.68M | 0.01% | 1486 |
|
|
2023
Q4 | $47.6M | Buy |
1,411,767
+17,949
| +1% | +$525K | 0.01% | 1484 |
|
|
2023
Q3 | $42.8M | Buy |
1,393,818
+271,544
| +24% | +$9.79M | 0.01% | 1456 |
|
|
2023
Q2 | $45M | Buy |
1,122,274
+133,097
| +13% | +$5.5M | 0.01% | 1433 |
|
|
2023
Q1 | $40.4M | Buy |
989,177
+41,808
| +4% | +$1.66M | 0.01% | 1489 |
|
|
2022
Q4 | $36.6K | Buy |
947,369
+70,141
| +8% | +$3.41M | 0.01% | 1516 |
|
|
2022
Q3 | $46.7M | Buy |
877,228
+67,892
| +8% | +$3.78M | 0.02% | 1285 |
|
|
2022
Q2 | $47.2M | Buy |
809,336
+50,941
| +7% | +$3.34M | 0.02% | 1331 |
|
|
2022
Q1 | $57.9M | Buy |
758,395
+3,602
| +0.5% | +$240K | 0.02% | 1295 |
|
|
2021
Q4 | $45.4M | Buy |
754,793
+40,191
| +6% | +$2.22M | 0.01% | 1483 |
|
|
2021
Q3 | $40M | Sell |
714,602
-68,290
| -9% | -$3.94M | 0.01% | 1576 |
|
|
2021
Q2 | $47.5M | Buy |
782,892
+169,324
| +28% | +$10.7M | 0.02% | 1490 |
|
|
2021
Q1 | $43M | Buy |
613,568
+37,851
| +7% | +$2.7M | 0.01% | 1563 |
|
|
2020
Q4 | $34.4M | Buy |
575,717
+18,553
| +3% | +$1.09M | 0.01% | 1664 |
|
|
2020
Q3 | $33.5M | Buy |
557,164
+12,857
| +2% | +$747K | 0.01% | 1515 |
|
|
2020
Q2 | $28.6M | Buy |
544,307
+15,972
| +3% | +$668K | 0.01% | 1642 |
|
|
2020
Q1 | $17.7M | Buy |
528,335
+22,550
| +4% | +$937K | 0.01% | 1828 |
|
|
2019
Q4 | $22.9M | Buy |
505,785
+2,941
| +0.6% | +$125K | 0.01% | 1963 |
|
|
2019
Q3 | $19.1M | Buy |
502,844
+77,525
| +18% | +$3.09M | 0.01% | 2044 |
|
|
2019
Q2 | $18.5M | Buy |
425,319
+73,207
| +21% | +$3.11M | 0.01% | 2094 |
|
|
2019
Q1 | $13.4M | Buy |
352,112
+111,505
| +46% | +$4.35M | 0.01% | 2270 |
|
|
2018
Q4 | $10.4M | Buy |
240,607
+180,425
| +300% | +$8.42M | ﹤0.01% | 2327 |
|
|
2018
Q3 | $2.96M | Buy |
+60,182
| New | +$2.6M | ﹤0.01% | 2825 |
|
|
2015
Q2 | – | Sell |
-46,790
| Closed | -$4.16M | – | 3369 |
|
|
2015
Q1 | $4.16M | Sell |
46,790
-3,270
| -7% | -$332K | ﹤0.01% | 2624 |
|
|
2014
Q4 | $4.44M | Buy |
50,060
+22,094
| +79% | +$2.09M | ﹤0.01% | 2600 |
|
|
2014
Q3 | $2.71M | Buy |
27,966
+19,962
| +249% | +$1.94M | ﹤0.01% | 2762 |
|
|
2014
Q2 | $735K | Buy |
+8,004
| New | +$609K | ﹤0.01% | 3103 |
|
Other funds holding PCRX
DPCM
VPM
VCM
Dimensional Fund Advisors's PCRX Position: Q1 2026 in Review
Dimensional Fund Advisors increased its Pacira BioSciences (PCRX) stake by 5.7% in Q1 2026, buying an estimated $2.46M and bringing the position to 2,060,597 shares worth $46.6M. The position accounts for 0.01% of the portfolio, ranked #1542.
Dimensional Fund Advisors first reported a position in PCRX in Q2 2014 and has held it in 35 quarters since. The position peaked at $57.9M in Q1 2022. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Dimensional Fund Advisors held 2,060,597 shares of Pacira BioSciences worth $46.6M as of Q1 2026.
- Dimensional Fund Advisors bought 110,584 Pacira BioSciences shares in Q1 2026, an estimated $2.46M.
- Pacira BioSciences made up 0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #1542 holding.
- Dimensional Fund Advisors first reported a position in Pacira BioSciences in Q2 2014 and has held it in 35 quarters since.
- Dimensional Fund Advisors's Pacira BioSciences position peaked at $57.9M in Q1 2022.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.